Beneficial effects of the combination of nifedipine and losartan in hypertensive Dahl salt-sensitive rats

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 1, 2007, Pages 75-82

  Tinel, Hanna ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Angiotensin II receptor blocker; Calcium channel blocker; Combination therapy; End organ damage; Hypertension; Losartan; Nifedipine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 3; COLLAGEN TYPE 4; LOSARTAN; MESSENGER RNA; NIFEDIPINE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE URINE LEVEL; DAHL SALT SENSITIVE RAT; DIET; DRUG EFFECT; DRUG EFFICACY; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; LOSARTAN; MALE; NATRIURETIC PEPTIDE, BRAIN; NIFEDIPINE; ORGAN SIZE; RATS; RATS, INBRED DAHL; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34547663211     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318058820c     Document Type: Article

References (47)

1. ESH/ESC Guidelines Committee. 2003 European Society of Hypertension Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
2. Ribeiro AB. Angiotensin II antagonists-therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Curr Med Res Opin. 2006;22:1-16.
3. Segura J, Garcia-Donaire JA, Ruilope LM. Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol. 2005;16:S64-S66.
4. Pontremoli R, Viazzi F, Ravera M, et al. Long term effect of nifedipine GITS and lisinopril on subclinical organ damage in patients with essential hypertension. J Nephrol. 2001;14:19-26.
5. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849-857.
6. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;34:861-869.
7. Kuschnir E, Bendersky M, Resk J, et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 2004;43:300-305.
8. Hasebe N, Kikuchi K. NICE Combi Study Group, Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens. 2005;23:445-453.
9. Dahl LK, Heine M, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature. 1962;194:480-482.
10. Mark AL, Victor RG, Ferrari A, et al. Cardiac sensory receptors in Dahl salt-resistant and salt-sensitive rats. Circulation. 1987;75:I137-I140.
11. Jaffe D, Sutherland LE, Barker DM, et al. Effects of chronic excess salt ingestion. Morphologic findings in kidneys of rats with differing genetic susceptibilities to hypertension. Arch Pathol. 1970;90:1-16.
12. Inoko M, Kihara Y, Morii I, et al. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol. 1994;267:H2471-H2482.
13. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986-994.
14. Miao CY, Yuan WJ, Su DF. Comparative study of sinoaortic denervated rats and spontaneously hypertensive rats. Am J Hypertens. 2003;16:585-591.
15. Su DF, Miao CY. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci. 2005;26:388-390.
16. Namba M, Kim S, Zhan Y, et al. Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension. Hypertens Res. 2002;25:461-466.
17. Yao K, Sato H, Ina Y, et al. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. Hypertens Res. 2003a;26:635-641.
18. Yao K, Sato, H, Sonoda R, et al. Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. Hypertens Res. 2003b;26:569-576.
19. Kim-Mitsuyama S, Izumi Y, Izumiya Y, et al. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res. 2004;27:771-779.
20. Luckhaus G, Garthoff B, Kazda S. Prevention of hypertensive vasculopathy by nifedipine in salt-loaded Dahl rats. Arzneimittelforschung. 1982;32:1421-1425.
21. Pontremoli R, Leoncini G, Parodi A. Use of nifedipine in the treatment of hypertension. Expert Rev Cardiovasc Ther. 2005;3:43-50.
22. Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens. 1998;12:301-309.
23. Devereux RB, Lyle PA. Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Expert Opin Pharmacother. 2004;5:2311-2320.
24. von Lutterotti N, Camargo MJ, Campbell WG Jr, et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens. 1992;10:949-957.
25. de Simone G, Devereux RB, Camargo MJ, et al. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens. 1996;9:216-222.
26. Kunes J, Hojna S, Kadlecova M, et al. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res. 2004;53:S23-S34.
27. Warren JH, Lewis W, Wraa CE, et al. Central and peripheral effects of angiotensin II on the cardiovascular response to exercise. J Cardiovasc Pharmacol. 2001;38:693-705.
28. Dendorfer A, Dominiak P, Tempel K, et al. Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy? J Hypertens. 2005;23:1861-1867.
29. Campo C, Saavedra J, Segura J, et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005;96:365-371.
30. Parati G. Blood pressure variability: its measurement and significance in hypertension. J Hypertens. 2005;23:S19-S25.
31. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
32. Jane-Lise S, Corda S, Chassagne C, et al. The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Fail Rev. 2000;5:239-250.
33. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond). 1998;95:519-529.
34. Christoffersen TE, Aplin M, Strom CC, et al. Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy. Am J Physiol. 2006;290:H1635-H1641.
35. Suo M, Kalliovalkama J, Porsti I, et al. N(G)-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism. J Cardiovasc Pharmacol. 2002;40:478-486.
36. Ruzicka M, Yuan B, Leenen FH. Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation. 1994;90:484-491.
37. de Simone G, Devereux RB, Camargo MJ, et al. Midwall left ventricular performance in salt-loaded Dahl rats: effect of AT1 angiotensin II inhibition. J Hypertens. 1995;13:1808-1812.
38. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13:80-93.
39. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290-301.
40. Camargo MJ, von Lutterotti N, Campbell WG Jr, et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens. 1993;11:31-40.
41. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
42. Baba S. J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54:191-201.
43. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists. Effects on cardiorenal risk in hypertensive patients. Hypertension. 2005;46:637-642.
44. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
45. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers. Am J Nephrol. 2006;26:462-468.
46. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8:634-641.
47. Sasaki H, Kanai S, Oyama T, et al. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2006;13:149-157.